Good morning, everyone, and welcome to another working week. We hope the extended respite — at least on this side of the pond — was relaxing and refreshing because the crushing routine of meetings, deadlines, texts, and conference calls has, predictably, returned. Summer is effectively over. But what can you do? The world keeps spinning and since the pause button is not an option, please join us for a delicious cup of stimulation — we are reaching for hazelnut creme today. Meanwhile, here are some tidbits to help you catch up. Hope your re-entry is manageable and do keep us in mind if something fascinating pops up. …

A proposed deal for Purdue Pharma to resolve more than 2,000 lawsuits over its role in the opioid crisis is facing pushback from a vocal group of state attorneys general who say it fails to bring in enough cash to satisfy their demands, according to The Wall Street Journal. Among the concerns is a reliance on future drug sales, how much money will be guaranteed, and contributions from the Sackler family, which owns the drug maker.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy